A widely cited sequence of reactions following the death of a loved one includes: disbelief, yearning (for the loved one’s return), anger, depression/mourning, and acceptance. Researchers conducted a study aimed at empirically assessing whether these stages actually occur and, if so, in what order.
On February 23, the FDA approved Shire and New River’s Vyvanse (lisdexamfetamine dimesylate) for the treatment of ADHD in children. Vyvanse is the molecule dextroamphetamine (trade names Dexedrine and Dextrostat) attached to the amino acid lysine.
Janssen’s marketing team apparently missed the fact that the word in the English language that sounds most like “Invega” is “inveigle,” meaning “to entice, lure, or ensnare by flattery or artful talk or inducements” (www.dictionary.com). You may have already heard some “artful talk” from your Janssen reps, who are keen to have you convert your patients from Risperdal to Invega.
In this article, guest author Dr. Shalom Feinberg, takes a hard look at the most recent data on the effectiveness of SGAs for depression in its various guises, including treatment-resistant depression (TRD) and bipolar depression (BD).
Dr. Carpenter, as Editor-in-Chief of Schizophrenia Bulletin and a long-time researcher in the field, I’m sure you’ve seen trends come and go. Lately, we’ve been hearing a lot about how the older, conventional antipsychotics may be just as good as the newer atypicals. What’s your take?
Adderall has overtaken Ritalin as the most-abused stimulant among college students. In a survey, 4,580 college students were asked about their illicit use of drugs.
An FDA advisory panel has recommended that TMS not be approved for the treatment of major depression. Neuronetics, the maker of the NeuroStar device (www.neuronetics.com), submitted data from three studies, but only one was a placebo-controlled double-blind trial (Study 101).
We often see teenagers with co-occurring bipolar disorder and aggressive/impulsive behaviors. While Depakote is often effective, we also often prescribe atypical antipsychotics. A new post-hoc analysis provides some evidence to bolster that practice.
Omega-3 fatty acids have been studied in a number of psychiatric disorders, including autism, bipolar disorder, depression, and schizophrenia. A new study shows a possible benefit for patients with a history of self-harm.